AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 221 min read

Medpace Holdings, Inc. Stock 12‑Month Price Target Raised to $624.33, Implies 6% Downside

Medpace Holdings' average stock price target increased from $614.75 to $624.33 by 12 analysts, with a range of $492 to $700. This implies a 6% downside from the Oct. 21 closing price. The consensus rating remains 'Hold' among 16 analysts.

Original reporting
tradingview.com
Published Oct 22, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 4:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medpace Holdings, Inc. Stock 12‑Month Price Target Raised to $624.33, Implies 6% Downside — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The price‑target increase reflects analyst optimism on future earnings but also signals limited upside, which may prompt short‑term selling.

02

Market read

Analyst target raise introduces modest downside pressure; limited broader market effect.

03

What to watch

Potential upcoming clinical trial data or contract wins could offset the implied downside.

Relevance 6/10Novelty 5/10Timing: post‑market today

Background

Medpace Holdings is a contract research organization providing clinical development services.

Market effects

Sector

Minimal impact on the broader healthcare services sector.

Regional

Limited to U.S. biotech/healthcare investors.

Global

Low

Counterpoint

What could challenge this read

Some investors may view the higher target as a buying opportunity if they believe the downside is overstated.

Key entities

  • company
    Medpace Holdings, Inc.

    Contract research organization

Read at source← All news

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min